RxDoctor Payments DataLook up a doctor →

Suman Pasupuleti, MD

Clinical Cardiac Electrophysiology · Inverness, FLNPI 1851503809

Payments from drug & device makers

$179,860in general payments, 2019–2025

Across 344 payments — averaging $522.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$99K
  • Novartis$28K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$22K
  • Abbott$14K
  • Johnson & Johnson$11K
  • Medtronic$2K
  • plus $3K from 31 others

What the payments were for

  • Consulting fees$2,8085%
  • Speaking & faculty fees$40,65071%
  • Travel & lodging$4,9159%
  • Food & beverage$8,87815%
  • Education$2230%
  • Other$380%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$179,860 in reported general payments places this provider in the 80th percentile of 249 clinical cardiac electrophysiology providers in Florida.

See all clinical cardiac electrophysiology providers in Florida

Medicare billing

Part B allowed, 2024
$1,084,222
Medicare patients
1,585
Services billed
11,311

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban305$395,049
XareltoRivaroxaban330$364,406
FarxigaDapagliflozin Propanediol242$284,241
EntrestoSacubitril/Valsartan152$188,308
Repatha SureclickEvolocumab39$53,256
JardianceEmpagliflozin27$44,845
Praluent PenAlirocumab25$19,765
NexlizetBempedoic Acid/Ezetimibe22$12,643
Metoprolol Succinate765$12,384
BrilintaTicagrelor12$11,219
Ranolazine ErRanolazine61$9,586
Atorvastatin Calcium623$8,611
Flecainide Acetate110$7,817
CorlanorIvabradine Hcl13$7,423
VascepaIcosapent Ethyl11$7,397

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$223$395,049305 claims
Johnson & JohnsonXarelto$11,154$364,406330 claims
AstraZenecaFarxiga, Brilinta$99,276$295,460254 claims
NovartisEntresto$28,319$188,308152 claims
Boehringer IngelheimJardiance$82$44,84527 claims
Esperion Therapeutics, Inc.Nexlizet$128$12,64322 claims
AmgenCorlanor$222$7,42313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 249 clinical cardiac electrophysiology providers in Florida.

Other clinical cardiac electrophysiology in Inverness

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →